Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Many patients with asthma or chronic obstructive pulmonary disease (COPD) routinely receive a combination of an inhaled bronchodilator and anti-inflammatory glucocorticosteroid, but those with severe disease often respond poorly to these classes of drug. We assessed the efficacy and safety of a novel inhaled dual phosphodiesterase 3 (PDE3) and PDE4 inhibitor, RPL554 for its ability to act as a bronchodilator and anti-inflammatory drug.

Detaljer

Författare
  • Lui G Franciosi
  • Zuzana Diamant
  • Katharine H Banner
  • Rob Zuiker
  • Nicoletta Morelli
  • Ingrid M C Kamerling
  • Marieke L de Kam
  • Jacobus Burggraaf
  • Adam F Cohen
  • Mario Cazzola
  • Luigino Calzetta
  • Dave Singh
  • Domenico Spina
  • Michael J A Walker
  • Clive P Page
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Lungmedicin och allergi
Originalspråkengelska
Sidor (från-till)714-727
TidskriftThe lancet. Respiratory medicine
Volym1
Utgåva nummer9
StatusPublished - 2013
PublikationskategoriForskning
Peer review utfördJa